Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA
- 1 July 2001
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 15 (10) , 1295-1302
- https://doi.org/10.1097/00002030-200107060-00012
Abstract
Human T-lymphotropic virus type II (HTLV-II) is widespread among injecting drug users (IDU) and may contribute to the risk of leukemia/lymphoma, neurodegenerative disease, and perhaps pneumonia, especially with HIV co-infection. In 1987–1991, 6570 IDU were tested for HIV and HTLV-II antibodies. In 1998, they were matched to the National Death Index. Numbers of observed deaths of each cause were compared by standardized mortality ratios with the numbers expected, using sex-, race-, age-, and year-specific rates in the general population. Relative risk (RR) associated with each virus, compared to uninfected drug users, was estimated by Poisson modeling. There were 1351 deaths, including 683 (15%) of 4604 participants who enrolled seronegative for both viruses; 328 (47%) of 701 who had HIV but not HTLV-II infection; 220 (21%) of 1033 who had HTLV-II but not HIV infection; and 120 (52%) of 232 who were infected by both viruses. Compared to the general population, mortality for participants with neither virus was increased 4.3-fold [95% confidence interval (CI), 4.0–4.7] and was significantly elevated for virtually every cause of death. With HIV, mortality from medical causes, but not external causes, was increased 3.7-fold (95% CI, 3.3–4.2), particularly with AIDS and related conditions. With HTLV-II, all-cause mortality was reduced (RR, 0.8; 95% CI, 0.7–0.9), with no statistically significant reduction or elevation for any specific cause. A non-significant excess of tuberculosis deaths (RR, 4.6; 95% CI, 0.8–25.2) was noted with HTLV-II, but there was no excess mortality from leukemia/lymphoma, other malignancies, or neurodegenerative disease. Without HIV or HTLV-II, IDU had profoundly increased mortality from medical and external causes. HIV was specifically associated with death due to AIDS and related conditions. HTLV-II infection was not significantly associated with mortality from any cause, suggesting that it is not a significant human pathogen, even when present with HIV infection.Keywords
This publication has 29 references indexed in Scilit:
- HTLV-II and Bacterial Infections Among Injection Drug UsersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Increased Frequency of Overdose Deaths Among HIV-Infected Injection Drug UsersAddiction Research, 2000
- Twenty-Five Years of HTLV Type II Follow-up with a Possible Case of Tropical Spastic Paraparesis in the Kayapo, a Brazilian Indian TribeAIDS Research and Human Retroviruses, 1996
- Human T Lymphotropic Virus Type II (HTLV-II): Epidemiology, Molecular Properties, and Clinical Features of InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progressionPublished by American Medical Association (AMA) ,1994
- Association of ‘(tropical) ataxic neuropathy’ with HTLV-IIVirus Research, 1993
- Isolation of HTLV‐II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV‐I‐associated myelopathy/tropical spastic paraparesisAnnals of Neurology, 1993
- In vivo cellular tropism of human T cell leukemia virus type II (HTLV-II).The Journal of Experimental Medicine, 1992
- Distinguishing between HTLV-I and HTLV-II by western blotThe Lancet, 1990
- A Second Isolate of HTLV-II Associated with Atypical Hairy-Cell LeukemiaNew England Journal of Medicine, 1986